These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 7769490)
1. Neuropeptide Y and regulation of the cardiovascular system. Shine J; Potter EK; Biden T; Selbie LA; Herzog H J Hypertens Suppl; 1994 Dec; 12(10):S41-5. PubMed ID: 7769490 [TBL] [Abstract][Full Text] [Related]
2. Neuropeptide Y analog with selective antagonism of effects mediated by postjunctional Y1 receptors. Tseng A; Inglis A; Selbie LA; Moriarty M; Potter EK Eur J Pharmacol; 1994 Dec; 271(2-3):265-71. PubMed ID: 7705427 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226. Lundberg JM; Modin A Br J Pharmacol; 1995 Dec; 116(7):2971-82. PubMed ID: 8680732 [TBL] [Abstract][Full Text] [Related]
4. Renal and cardiovascular role of the neuropeptide Y Y1 receptor in ischaemic heart failure rats. Zhao XH; Sun XY; Bergdahl A; Edvinsson L; Hedner T J Pharm Pharmacol; 1999 Nov; 51(11):1257-65. PubMed ID: 10632083 [TBL] [Abstract][Full Text] [Related]
5. Stimulation of the sympathetic perimesenteric arterial nerves releases neuropeptide Y potentiating the vasomotor activity of noradrenaline: involvement of neuropeptide Y-Y1 receptors. Donoso MV; Brown N; Carrasco C; Cortes V; Fournier A; Huidobro-Toro JP J Neurochem; 1997 Sep; 69(3):1048-59. PubMed ID: 9282927 [TBL] [Abstract][Full Text] [Related]
6. Does the neuropeptide Y Y1 receptor contribute to blood pressure control in the spontaneously hypertensive rat? Zhao XH; Sun XY; Edvinsson L; Hedner T J Hypertens; 1997 Jan; 15(1):19-27. PubMed ID: 9050966 [TBL] [Abstract][Full Text] [Related]
7. SR 120107A antagonizes neuropeptide Y Y1 receptor mediated sympathetic vasoconstriction in pigs in vivo. Malmström RE; Modin A; Lundberg JM Eur J Pharmacol; 1996 Jun; 305(1-3):145-54. PubMed ID: 8813545 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist. Antal-Zimanyi I; Bruce MA; Leboulluec KL; Iben LG; Mattson GK; McGovern RT; Hogan JB; Leahy CL; Flowers SC; Stanley JA; Ortiz AA; Poindexter GS Eur J Pharmacol; 2008 Aug; 590(1-3):224-32. PubMed ID: 18573246 [TBL] [Abstract][Full Text] [Related]
10. An overview of neuropeptide Y: pharmacology to molecular biology and receptor localization. Dumont Y; Quirion R EXS; 2006; (95):7-33. PubMed ID: 16382995 [No Abstract] [Full Text] [Related]
11. Pancreatic polypeptide-fold peptide receptors and angiotensin II-induced renal vasoconstriction. Dubinion JH; Mi Z; Zhu C; Gao L; Jackson EK Hypertension; 2006 Mar; 47(3):545-51. PubMed ID: 16365188 [TBL] [Abstract][Full Text] [Related]
12. GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists. Parker EM; Babij CK; Balasubramaniam A; Burrier RE; Guzzi M; Hamud F; Mukhopadhyay G; Rudinski MS; Tao Z; Tice M; Xia L; Mullins DE; Salisbury BG Eur J Pharmacol; 1998 May; 349(1):97-105. PubMed ID: 9669502 [TBL] [Abstract][Full Text] [Related]
13. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy. Michel MC; Gaida W; Beck-Sickinger AG; Wieland HA; Doods H; Dürr H; Jung G; Schnorrenberg G Mol Pharmacol; 1992 Oct; 42(4):642-8. PubMed ID: 1331755 [TBL] [Abstract][Full Text] [Related]
14. Characterization of vascular postsynaptic neuropeptide Y receptor function and regulation. 1. NPY-induced constriction in isolated rat femoral artery rings is mediated by both Y1 and Y2 receptors: evidence from benextramine protection studies. Tessel RE; Miller DW; Misse GA; Dong X; Doughty MB J Pharmacol Exp Ther; 1993 Apr; 265(1):172-7. PubMed ID: 8474004 [TBL] [Abstract][Full Text] [Related]
15. Neuropeptide Y: a possible role in hypertension? Michel MC; Rascher W J Hypertens; 1995 Apr; 13(4):385-95. PubMed ID: 7629398 [TBL] [Abstract][Full Text] [Related]
16. Antagonistic regulation of alpha 2-adrenoceptors by neuropeptide Y receptor subtypes in the nucleus tractus solitarii. Yang SN; Fior DR; Hedlund PB; Agnati LF; Fuxe K Eur J Pharmacol; 1994 Dec; 271(1):201-12. PubMed ID: 7698202 [TBL] [Abstract][Full Text] [Related]
17. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype. Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275 [TBL] [Abstract][Full Text] [Related]
18. Pharmacology of H 394/84, a dihydropyridine neuropeptide Y Y(1) receptor antagonist, in vivo. Malmström RE; Balmér KC; Weilitz J; Nordlander M; Sjölander M Eur J Pharmacol; 2001 Apr; 418(1-2):95-104. PubMed ID: 11334870 [TBL] [Abstract][Full Text] [Related]
19. Neuropeptide Y as a partial agonist of the Y1 receptor. Sah R; Balasubramaniam A; Parker MS; Sallee F; Parker SL Eur J Pharmacol; 2005 Nov; 525(1-3):60-8. PubMed ID: 16293244 [TBL] [Abstract][Full Text] [Related]
20. Pharmacology of neuropeptide Y receptor antagonists. Focus on cardiovascular functions. Malmström RE Eur J Pharmacol; 2002 Jun; 447(1):11-30. PubMed ID: 12106798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]